Colorado is currently home to 1810 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Denver, Aurora, Colorado Springs and Englewood. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
A U.S. Registry of Eosinophilic Esophagitis Adolescent and Adult Patients Treated With DUPIXENT® As Standard of Care
NCT06693531
Recruiting
This observational research study is to better understand patients with eosinophilic esophagitis (EoE) who have recently been prescribed DUPIXENT® (dupilumab). The purpose of this research study is to look at how DUPIXENT is used in normal care of patients with EoE. Possible benefits to others include a better understanding of EoE and helping to inform research and clinical trial design leading to treatment decisions in this patient population going forward. Patient questionnaires will measure... Read More
Gender:
ALL
Ages:
12 years and above
Trial Updated:
08/06/2025
Locations: Childrens Hospital Colorado, Aurora, Colorado
Conditions: Eosinophilic Esophagitis (EoE)
Register for Updates
A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma
NCT06664619
Recruiting
The primary objective of the trial is to evaluate the efficacy of fluticasone propionate/albuterol sulfate multidose dry powder inhaler with electronic module (Fp/ABS eMDPI). Secondary objectives are: * To evaluate the efficacy of Fp/ABS eMDPI administered four times daily * To evaluate the safety and tolerability of Fp/ABS eMDPI administered four times daily over four weeks * To investigate the pharmacokinetics of Fp/ABS eMDPI, ABS eMDPI and Fp eMDPI after administration of a single dose The... Read More
Gender:
ALL
Ages:
12 years and above
Trial Updated:
08/06/2025
Locations: Teva Investigational Site 12142, Lakewood, Colorado
Conditions: Asthma
Register for Updates
Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML
NCT06578247
Recruiting
This study will compare the effects of Quizartinib versus placebo in combination with chemotherapy in participants with newly diagnosed FMS-like tyrosine kinase 3 (FLT3)-internal tandem duplication (ITD) negative acute myeloid leukemia (AML).
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
08/06/2025
Locations: Colorado Blood Cancer Institute, Denver, Colorado
Conditions: Leukemia
Register for Updates
A Phase 2a Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases
NCT06570798
Recruiting
The main objective is to assess the safety and tolerability of inebilizumab in adult participants with active and refractory systemic lupus erythematosus (SLE) with nephritis (Subprotocol A) and to assess the safety and tolerability of subcutaneous (SC) blinatumomab in adult participants with active and refractory SLE with nephritis (Subprotocol B) and in adult participants with active refractory rheumatoid arthritis (RA) (Subprotocol C).
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
08/06/2025
Locations: University of Colorado, Aurora, Colorado
Conditions: Systemic Lupus Erythematosus, Active Refractory Rheumatoid Arthritis
Register for Updates
"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder"
NCT06564818
Recruiting
The purpose of this study is to examine the efficacy, safety, and tolerability of CYB003 compared to matching placebo as adjunctive treatment in participants with MDD.
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
08/06/2025
Locations: Mountain View Clinical Research, Denver, Colorado
Conditions: Major Depressive Disorder
Register for Updates
Volrustomig Priming Regimens Exploratory Phase II Platform Study
NCT06448754
Recruiting
Purpose of this study is to assess the safety, tolerability, pharmacokinetics, immunogenicity, and antitumor activity of volrustomig in combination with other anticancer drugs in participants with specified solid tumors.
Gender:
ALL
Ages:
Between 18 years and 130 years
Trial Updated:
08/06/2025
Locations: Research Site, Grand Junction, Colorado
Conditions: Non-small Cell Lung Cancer
Register for Updates
A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)
NCT06246916
Recruiting
This study is researching an experimental drug called fianlimab (also known as REGN3767), combined with another medication called cemiplimab (also known as REGN2810), called "study drugs". The study is focused on patients with a type of skin cancer known as melanoma. The aim of the study is to see how safe and effective the combination of fianlimab and cemiplimab is in treating melanoma, in comparison with the combination of two medications, relatlimab and nivolumab, commercialized under the bra... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/06/2025
Locations: Rocky Mountain Regional VA Medical Center, Aurora, Colorado
Conditions: Melanoma
Register for Updates
A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors
NCT06157892
Recruiting
This clinical trial is studying solid tumor cancers. A solid tumor is one that starts in part of your body like your lungs or liver instead of your blood. Once they've grown bigger in one spot or spread to other parts of the body, they're harder to treat. This is called advanced or metastatic cancer. Participants in this study must have breast cancer or gastric cancer. Participants must have tumors that have HER2 on them. This allows the cancer to grow more quickly or spread faster. There are f... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/06/2025
Locations: Colorado West Healthcare System, dba Community Hospital, Grand Junction, Colorado
Conditions: Breast Neoplasms, Gastroesophageal Junction Adenocarcinoma, HER2 Low Breast Neoplasms, HER2 Positive Breast Neoplasms, Stomach Neoplasms, Triple Negative Breast Neoplasms, Metastatic Breast Cancer, Metastatic Gastric Cancer, Advanced Breast Cancer, Advanced Gastric Cancer
Register for Updates
Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents
NCT06120491
Recruiting
The intention of the study is to demonstrate superiority of Saruparib (AZD5305) + physician's choice NHA relative to placebo + physician's choice NHA by assessment of radiographic progression-free survival (rPFS) in participants with mCSPC.
Gender:
MALE
Ages:
Between 18 years and 130 years
Trial Updated:
08/06/2025
Locations: Research Site, Golden, Colorado
Conditions: Metastatic Castration-Sensitive Prostate Cancer
Register for Updates
A Study of Alisertib in Patients With Extensive Stage Small Cell Lung Cancer
NCT06095505
Recruiting
PUMA-ALI-4201 is a Phase 2 study evaluating alisertib monotherapy in patients with pathologically-confirmed small cell lung cancer (SCLC) following progression on or after treatment with one platinum-based chemotherapy and anti-PD-L1 immunotherapy agent. Up to one additional systemic anti-cancer therapy for SCLC is allowed, for a total of up to two prior lines of therapy. This study is intended to identify the biomarker-defined subgroup(s) that may benefit most from alisertib treatment and to ev... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/06/2025
Locations: Rocky Mountain Cancer Centers, Lone Tree, Colorado
Conditions: Small Cell Lung Cancer
Register for Updates
A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer.
NCT05984277
Recruiting
The purpose of eVOLVE-Lung02 is to test the effectiveness (efficacy) and measure the safety of volrustomig in combination with chemotherapy compared with pembrolizumab in combination with chemotherapy as 1L treatment in participants with mNSCLC in PD-L1 \< 50%.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/06/2025
Locations: Research Site, Lone Tree, Colorado
Conditions: Metastatic Non-small Cell Lung Cancer
Register for Updates
The THOR IDE Study
NCT05916950
Recruiting
The goal of this clinical trial is to test the Thor system in adult (≥ 18 year old) patients with de novo (new, never treated) calcified lesions in infrainguinal (leg) arteries (peripheral artery disease or PAD). The main question\[s\] it aims to answer are: * Is the Thor system safe in treating these lesions * Does the Thor system work to treat these lesions Participants will: * Receive treatment with the Thor system * Have follow-up visits at Discharge, 30 days, 6 months, and 12 months
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/06/2025
Locations: Rocky Mountain Regional VA Medical Center, Aurora, Colorado
Conditions: Peripheral Artery Disease, Peripheral Artery Stenosis, Peripheral Artery Calcification, PAD
Register for Updates